Welcome to our dedicated page for ONXEO news (Ticker: ONXEO), a resource for investors and traders seeking the latest updates and insights on ONXEO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONXEO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONXEO's position in the market.
ONXEO reported its liquidity contract activity for the period ending December 31, 2022. The liquidity account showed 575,697 shares and €10,983.50. Over the semester, there were 349 buy executions totaling 335,452 shares valued at €82,028.30, while 236 sell executions involved 208,189 shares for €59,090.63. Comparatively, on June 30, 2022, the account held 448,434 shares with €33,899.60. This report follows the AMF Decision N°2021-01 regarding liquidity contracts as market practices.
Onxeo, a biotechnology company, reported a net loss of €11.5 million for the first half of 2022, an increase from €4.8 million in the same period of 2021. Operating expenses rose to €9.6 million, driven by higher R&D costs of €4.1 million, primarily for AsiDNA's development. The cash position improved to €26.9 million, ensuring financial stability until Q2 2023. Highlights include FDA approval for AsiDNA's IND application and ongoing Phase 1b/2 trials. Future plans focus on advancing clinical trials and expanding the OX400 compound's development.
Onxeo S.A. (Ticker: ONXEO) announced the enrollment and treatment of the first patient in its phase 1b/2 clinical study for AsiDNA, a first-in-class DNA Damage Response inhibitor. This trial targets relapsed High-Grade Glioma (HGG) in children and adolescents. With HGG accounting for 20% of CNS tumors in children and a grim 5-year survival rate below 20%, this study aims to demonstrate efficacy and tolerability when combined with radiotherapy. The trial is sponsored by Institut Curie and aims to enroll 32 patients, with interim results expected in Q1 2024.
Onxeo, a clinical-stage biotechnology company, announced the approval of the delisting of its shares from Nasdaq's First North Growth market, effective November 8, 2022. This decision follows the Combined General Meeting's resolution from August 17, 2022. Onxeo shares will continue trading on Euronext Growth Paris. Danish shareholders will automatically exchange their shares for French shares at a one-to-one ratio, incurring no costs. The exchange process is expected to maintain identical rights for shareholders under the same ISIN. Shareholders objecting to the exchange must notify their banks by the deadline.
Onxeo S.A. (Euronext Paris: ALONX, Nasdaq First North: ONXEO) plans to delist from Nasdaq First North following shareholder approval at a recent meeting. The Board of Directors has been authorized to execute the delisting, which is expected to be finalized within 10 weeks post-approval by the exchange operator. Danish shareholders will be able to trade their shares on Euronext Growth, maintaining the same ISIN code. No changes will be made to the share capital or rights attached to shares during this transition.
Onxeo S.A. (Euronext: ONXEO), a biotechnology firm focused on innovative cancer drugs, has made preparatory documents available for its Combined General Meeting scheduled for August 17, 2022. Shareholders can participate by attending in person, voting by mail, or by proxy. Important documents, including a report detailing the implications of the company’s delisting from the Nasdaq First North market, can be accessed on their website. The company is developing drugs targeting tumor DNA damage response, including the clinical-stage candidate AsiDNA and the upcoming OX400 series.
Onxeo has announced a Combined General Meeting on August 17, 2022, at 2:00 pm CEST in Paris. Shareholders will vote on the proposal to delist from Nasdaq First North to consolidate listing on Euronext Growth, potentially enhancing liquidity. Meeting details and documents will be made available on the company’s website as required.
Onxeo specializes in innovative oncology drugs targeting DNA Damage Response (DDR) and is developing compounds like AsiDNA and the OX400 series, which focus on overcoming tumor resistance and enhancing immune response.
On June 30, 2021, ONXEO reported liquidity contract details with Kepler Cheuvreux. The liquidity account held 448,434 shares and €33,899.60. During the semester, there were 255 buy-side executions for 269,935 shares worth €99,624.74, and 222 sell-side executions for 251,351 shares worth €96,727.03. In the previous half-year statement on December 31, 2021, the account had 429,850 shares and €36,891.92. The report complies with AMF Decision N°2021-01, renewing liquidity contracts as an accepted market practice.
Onxeo has received FDA clearance for its first U.S. Investigational New Drug (IND) application for AsiDNA, enabling the initiation of a Phase 1b/2 clinical trial. This trial will evaluate the safety and efficacy of AsiDNA in combination with the PARP inhibitor Olaparib for patients with solid tumors who have previously progressed on PARP therapy. The company aims to start this multicenter trial in the second half of 2022 across 3-5 clinical sites in the U.S. This marks a significant milestone since the establishment of the U.S. team in April 2022.
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) held a Combined General Meeting where all resolutions were approved in line with Board recommendations. Notably, shareholders appointed Mr. Khalil Barrage as a new Board member for three years. Mr. Barrage, Managing Director of Invus, is expected to enhance ties with the Company’s main shareholder. The Board now comprises eight members, five of whom are independent. Upcoming financial communication includes the 2022 Half-Year accounts on September 13, 2022.
